B-lymphocytes as targets for therapy in chronic cold agglutinin disease

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 7, Issue 3, 2007, Pages 219-227

  Berentsen, Sigbjørn ^a   Ulvestad, Elling ^b   Tjønnfjord, Geir E ^c  

^a HAUGESUND HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

B lymphocytes; Cold agglutinin disease; Fludarabine; Hemolytic anemia; Lymphoproliferative; Rituximab

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; CD20 ANTIGEN; CLADRIBINE; COLD AGGLUTININ; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CORTICOSTEROID; CYTOTOXIC AGENT; ECULIZUMAB; ERYTHROCYTE ANTIGEN; FC RECEPTOR; FC RECEPTOR IIIA; FLUDARABINE; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M KAPPA CHAIN; PURINE DERIVATIVE; RITUXIMAB; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; B LYMPHOCYTE; BLOOD TOXICITY; BONE MARROW BIOPSY; CHRONIC COLD AGGLUTININ DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DERMATITIS; DRUG POTENTIATION; DRUG RESPONSE; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; GENETIC CODE; GENETIC POLYMORPHISM; HEMOGLOBINURIA; HEMOLYTIC ANEMIA; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION; LYMPHOCYTE SUBPOPULATION; MONOTHERAPY; NAUSEA; PATHOGENESIS; REVIEW; UNSPECIFIED SIDE EFFECT;

AGGLUTININS; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANIMALS; ANTIGENS, CD20; B-LYMPHOCYTES; COMPLEMENT SYSTEM PROTEINS; HUMANS;

EID: 34848877416     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152907781745279     Document Type: Review

References (82)

1. Dacie, J. Auto-immune haemolytic anaemia (MRA): cold antibody syndromes I: idiopathic types: clinical presentation and haematological and serological findings. In The Haemolytic Anaemias, Vol. 3; Dacie, J.; Ed., Churchill Livingstone: London, 1992; pp. 210-239.
2. Ulvestad, E.; Berentsen, S.; Bo, K.; Shammas, F. V. Clinical immunology of chronic cold agglutinin disease. Eur J. Haematol., 1999, 63(4), 259-266.
3. Dacie, J. Auto-immune haemolytic anaemia (AIHA): cold-antibody syndromes II: immunochemistry and specificity of the antibodies; serum complement in auto-immune haemolytic anaemia. In The Haemolytic Anaemias, Vol. 3; Dacie, J.; Ed.; Churchill Livingstone: London, 1992; pp. 240-295.
4. Harboe, M.; Torsvik, H. Protein abnormalities in the cold haemag-glutinin syndrome. Scand. J. Haematol., 1969, 6(6), 416-426.
5. Berentsen, S.; Ulvestad, E.; Langholm, R.; Beiske, K.; Hjorth-Hansen, H.; Ghanima, W.; Sorbo, J. H.; Tjonnfjord, G. E. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica, 2006, 9(4), 460-466.
6. Olesen, H. Thermodynamics of the cold agglutinin reaction. Scand. J. Clin. Lab. Invest., 1966, 18(1), 1-15.
7. Rosse, W. F.; Adams, J. P. The variability of hemolysis in the cold agglutinin syndrome. Blood, 1980, 56(3), 409-416.
8. Zilow, G.; Kirschfink, M.; Roelcke, D. Red cell destruction in cold agglatinin disease. Infusionsther. Transfusionsmed, 1994, 21(6), 410-415.
9. Schubothe, H. The cold hemagglutinin disease. Semin. Hematol., 1966, 3(1), 27-47.
10. Kirschfink, M.; Knoblauch, K.; Roelcke, D. Activation of complement by cold agglutinins. Infusionsther. Transfusionsmed, 1994, 2(6), 405-409.
11. Dacie, J. The auto-immune haemolytic anaemias: introduction. In The Haemolytic Anaemias, Vol. 3; Dacie, J.; Ed.; Churchill Livingstone: London, 1992; pp. 1-5.
12. Nydegger, U. E.; Kazatchkine, M. D.; Miescher, P. A. Immunopathologic and clinical features of hemolytic anemia due to cold agglutinins. Semin. Hematol., 1991, 28(1), 66-77.
13. Hadnagy, C. Agewise distribution of idiopathic cold agglutinin disease. Z. Gerontol., 1993, 26(3), 199-201.
14. Sokol, R. J.; Hewitt, S.; Stamps, B. K. Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre. Br. Med. J., (Clin. Res. Ed) 1981, 282(6281), 2023-2027.
15. Genty, I.; Michel, M.; Hermine, O.; Schaeffer, A.; Godeau, B.; Rochant, H. [Characteristics of autoimmune hemolytic anemia in adults: retrospective analysis of 83 cases]. Rev. Med. Interne., 2002, 23(11), 901-909.
16. Berentsen, S.; Bo, K.; Shammas, F. V.; Myking, A. O.; Ulvestad, E. Chronic cold agglutinin disease of the "idiopathic" type is a premalignant or low-grade malignant lymphoproliferative disease. APMIS., 1997, 105(5), 354-362.
17. Lyckholm, L. J.; Edmond, M. B. Images in clinical medicine. Seasonal hemolysis due to cold-agglutinin syndrome. N. Engl. J. Med., 1996, 334(7).437.
18. Ulvestad, E. Paradoxical haemolysis in a patient with cold agglutinin disease. Eur. J. Haematol., 1998, 60(2), 93-100.
19. Ulvestad, E.; Berentsen, S.; Mollnes, T. E. Acute phase haemolysis in chronic cold agglutinin disease. Scand. J. Immunol., 2001, 54(1-2), 239-242.
20. Dacie, J. Treatment and prognosis of cold-antibody AIHA. In The Haemolytic Anaemias, Vol. 3; Dacie, J.; Ed.; Churchill Livingstone: London, 1992; pp. 502-508.
21. Gehrs, b. C.; Friedberg, R. C. Autoimmune hemolytic anemia. Am. J. Hematol., 2002, 69(4), 258-271.
22. Worlledge, S. M.; Brain, M. C.; Cooper, A. C.; Hobbs, J. R.; Dacie, J. Immmunosuppressive drugs in the treatment of autoimmune haemolytic anaemia. Proc. R. Soc. Med., 1968, 61(12), 1312-1315.
23. Hippe, E.; Jensen, K. B.; Olesen, H.; Lind, K.; Thomsen, P. E. Chlorambucil treatment of patients with cold agglutinin syndrome. Blood, 1970, 35(1), 68-72.
24. Hillen, H. F.; Bakker, S. J. Failure of interferon-alpha-2b therapy in chronic cold agglutinin disease. Eur J. Haematol., 1994, 53(4), 242-243.
25. Berentsen, S.; Tjonnfjord, G. E.; Shammas, F. V.; Bergheim, J.; Hammerstrom, J.; Langholm, R.; Ulvestad, E. No response to cladribine in five patients with chronic cold agglutinin disease. Eur. J. Haematol., 2000, 65(1), 88-90.
26. Monteverde, A.; Rivano, M. T.; Allegra, G. C.; Monteverde, A. I.; Zigrossi, P.; Baglioni, P.; Gobbi, M.; Falini, B.; Bordin, G.; Pileri, S. Essential mixed cryoglobulinemia, type II: a manifestation of a low-grade malignant lymphoma? Clinical-morphological study of 12 cases with special reference to immunohistochemical findings in liver frozen sections. Acta Haematol., 1988, 79(1), 20-25.
27. Rørvik, K. The syndrome of high-titre cold haemagglutination; a survey and a case report. Acta Med. Scand., 1954, 148(4), 299-308.
28. Dellagi, K.; Brouet, J. C.; Schenmetzler, C.; Praloran, V. Chronic hemolytic anemia due to a monoclonal IgG cold agglutinin with anti-Pr specificity. Blood, 1981, 57(1), 189-191.
29. Jaffe, C. J.; Atkinson, J. P.; Frank, M. M. The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man. J. Clin. Invest., 1976, 58(4), 942-949.
30. Lewis, S. M.; Szur, L.; Dacie, J. V. The pattern of erythrocyte destruction in haemolytic anaemia, as studied with radioactive chromium. Br. J. Haematol., 1960, 6, 122-139.
31. Rosse, W. F.; Hillmen, P.; Schreiber, A. D. Immune-mediated hemolytic anemia, Hematology. (Am. Soc. Hematol. Educ. Program) 2004, 48-62.
32. Christenson, W. N.; Dacie, J. V.; Croucher, B. E.; Charlwood, P. A. Electrophoretic studies on sera containing high-titre cold haemagglutinins: identification of the antibody as the cause of an abnormal gamma 1 peak. Br. J. Haematol., 1957, 3(3), 262-275.
33. Harboe, M.; Deverill, J. Immunochemical properties of cold haemagglutinins. Scand J. Haematol., 1964, 61, 223-237.
34. Harboe, M.; van Furth, R.; Schubothe, H.; Lind, K.; Evans, R. S. Exclusive occurrence of K chains in isolated cold haemagglutinins. Scand. J. Haematol., 1965, 2(3), 259-266.
35. Stone, M. J.; McElroy, Y. G.; Pestronk, A.; Reynolds, J. L.; Newman, J. T.; Tong, A. W. Human monoclonal macroglobulins with antibody activiy. Semin. Oncol., 2003, 30(2), 318-324.
36. Hughey, C. T.; Brewer, J. W.; Colosia, A. D.; Rosse, W. F.; Corley, R. B. Production of IgM hexamers by normal and autoimmune B cells: implications for the physiologic role of hexameric IgM. J. Immunol., 1998, 161(8), 4091-4097.
37. Randall, T. D.; King, L. B.; Corley, R. B. The biological effects of IgM hexamer formation. Eur J. Immunol., 1990, 20(9), 1971-1979.
38. Pascual, V.; Victor, K.; Spellerberg, M.; Hamblin, T. J.; Stevenson, F. K.; Capra, J. D. VH restriction among human cold agglutinins. The VH4-21 gene segment is required to encode anti-I and anti-i specificities. J. Immunol., 1992, 149(7), 2337-2344.
39. Thorpe, S. J.; Boult, C. E.; Stevenson, F. K.; Scott, M. L.; Sutherland, J.; Spellerberg, M. B.; Natvig, J. B.; Thompson, K. M. Cold agglutinin activity is common among human monoclonal IgM Rh system antibodies using the V4-34 heavy chain variable gene segment. Transfusion, 1997, 37(11-12), 1111-1116.
40. Potter, K. N. Molecular characterization of cold agglutinins. Transfus. Sci., 2000, 22(1-2), 113-119.
41. Jefferies, L. C.; Carchidi, C. M.; Silberstein, L. E. Naturally occurring anti-i/I cold agglutinins may be encoded by different VH3 genes as well its the VH4.21 gene segment. J. Clin. Invest., 1993, 92(6), 2821-2833.
42. Jonsen, J.; Kass, E.; Harboe, M. Complement and complement components in acquired hemolytic anemia with high titer cold antibodies. Acta Med. Scand. 1961, 170, 725-729.
43. Berentsen, S.; Ulvestad, E.; Gjertsen, B. T.; Hjorth-Hansen, H.; Langholm, R.; Knutsen, H.; Ghanima, W.; Shammas, F. V.; Tjonnfjord, G. E. Rituximab for primary chronic cold agglutinin disease: a prospective study of37 courses of therapy in 27 patients. Blood, 2004, 103(8), 2925-2928.
44. Harjunpaa, A. Junnikkala, S.; Meri, S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand. J. Immunol., 2000, 51(6), 634-641.
45. Golay, J.; Cittera, E.; Di Gaetano, N.; Manganini, M.; Mosca, M.; Nebuloni, M.; van Rooijen, N.; Vago, L.; Introna, M. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica, 2006, 91(2), 176-183.
46. Silberstein, L. E.; Robertson, G. A.; Harris, A. C.; Moreau, L.; Besa, E.; Nowell, P. C. Etiologic aspects of cold agglutinin disease: evidence for cytogenetically defined clones of lymphoid cells and the demonstration that an anti-Pr cold autoantibody is derived from a chromosomally aberrant B cell clone. Blood, 1986, 67(6), 1705-1709.
47. Berentsen, S. [Chronic cold agglutinin disease]. Tidsskr. Nor Laegeforen, 1995, 115(4), 473-475.
48. Isaksson, E.; Bjorkholm, M.; Holm, G.; Johansson, B.; Nilsson, B.; Mellstedt, H.; Osterborg, A. Blood clonal B-cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): association with malignant transformation. Br. J. Haematol., 1996, 92(1), 71-76.
49. Berger, F.; Isaacson, P. G.; Piris, M. A.; Harris, N. L.; Müller-Hermelink, H. K.; Nathwani, B. N.; Swerdlow, S. H. Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. In Pathology and genetics of tumours of the haematopoietic and lymphoid tissues. WHO classification of tumours, Vol. 3; Jaffe, E. S.; Harris, N. L.; Stein, H.; Vardiman, J.; Ed.; IARC Press: Lyon, 2001; pp. 132-134.
50. Owen, R. G.; Treon, S. P.; Al Katib, A.; Fonseca, R.; Greipp, P. R.; McMaster, M. L.; Morra, E.; Pangalis, G. A.; San Miguel, J. F.; Branagan, A. R.; Dimopoulos, M. A. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin. Oncol., 2003, 30(2), 110-115.
51. Crisp, D.; Pruzanski, W. B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am. J. Med., 1982, 72(6), 915-922.
52. Dacie, J. Haemolytic anaemias associated with malignant lymphomas other than Hodgkin's disease and chronic lymphocytic leukaemia. (CLL). In The Haemolytic Anaemias, Vol. 4; Dacie, J.; Ed.; Churchill Livingstone: London, 1995; pp. 27-40.
53. Maloney, D. G.; Grillo-Lopez, A. J.; Bodkin, D. J.; White, C. A.; Liles, T. M.; Royston, I.; Varns, C.; Rosenberg, J.; Levy, R. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol., 1997, 15(10), 3266-3274.
54. McLaughlin, P.; Grillo-Lopez, A. J.; Link, B. K.; Levy, R.; Czuczman, M. S.; Williams, M. E.; Heyman, M. R.; Bence-Bruckler, I.; White, C. A.; Cabanillas, F.; Jain, V.; Ho, A. D.; Lister, J.; Wey, K.; Shen, D.; Dallaire, B. K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol., 1998, 16(8), 2825-2833.
55. Lee, E. J.; Kueck, B. Rituxan in the treatment of cold agglutinin disease. Blood, 1998, 92(9), 3490-3491.
56. Berentsen, S.; Tjonnfjord, G. E.; Brudevold, R.; Gjertsen, B. T.; Langholm, R.; Lokkevik, E.; Sorbo, J. H.; Ulvestad, E. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br. J. Haematol., 2001, 115(1), 79-83.
57. Schollkopf, C.; Kjeldsen, L.; Bjerrum, O. W.; Mourits-Andersen, H. T.; Nielsen, J. L.; Christensen, B. E.; Jensen, B. A.; Pedersen, B. B.; Taaning, E. B.; Klausen, T. W.; Birgens, H. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk. Lymphoma, 2006, 47(2), 253-260.
58. Finazzi, G. Rituximab in autoimmune cytopenias: for which patients? Haematologica, 2002, 87(2), 113-114.
59. Carnou, F.; Viallard, J. F.; Pellegrin, J. L. [Rituximab in cold agglutinin disease]. Rev. Med. Interne., 2003, 24(8), 501-504.
60. Robak, T. Monoclonal antibodies in tile treatment of autoimmune cytopenias. Eur. J. Haematol., 2004, 72(2), 79-88.
61. Cooper, N.; Stasi, R.; Cunningham-Rundles, S.; Feuerstein, M. A.; Leonard, J. P.; Amadori, S.; Bussel, J. B. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br. J. Haematol.; 2004, 125(2), 232-239.
62. Ghielmini, M.; Schmitz, S. F.; Cogliatti, S. B.; Pichert, G.; Hummerjohann, J.; Waltzer, U.; Fey, M. F.; Betticher, D. C.; Martinelli, G.; Peccatori, F.; Hess, U.; Zucca, E.; Stupp, R.; Kovacsovics, T.; Helg, C.; Lohri, A.; Bargetzi, M.; Vorobiof, D.; Cerny, T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood, 2004, 103(12), 4416-4423.
63. Wirths, S.; Ruprecht, C.; Bertoni, F.; Kanz, L.; Lanzavecchia, A. Hierachy of human B cell regeneration after rituximab therapy [48. annual meeting of the American Society of Hematology, Orlando, Abstract 936]. Blood, 2006, 108(11).279a.
64. Cesana, C.; Barbarano, L.; Miqueleiz, S.; Lucchesini, C.; Ricci, F.; Varettoni, M.; Filippini, D.; Lazzarino, M.; Morra, E. Clinical Characteristics and Outcome of Immunoglobulin MRelated Disorders. Clin. Lymphoma, 2005, 5(4), 261-264.
65. Merlini, G.; Stone, M. J. Dangerous small B-cell clones. Blood, 2006, 108(8), 2520-2530.
66. Kimby, E. Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte colony stimulating factor [corrected]. Semin. Oncol., 2002, 29(2 Suppl 6), 7-10.
67. Ulvestad, E.; Aarseth, J. H.; Vedeler, C.; Nyland, H.; Myhr, K. M. The effects of interferon-alpha2a on concentrations of immunoglobulins, complement and lymphocytes in patients with multiple sclerosis. Scand. J. Immunol., 2004, 59(1), 103-108.
68. Golay, J.; Lazzari, M.; Facchinetti, V.; Bernasconi, S.; Borleri, G.; Barbui, T.; Rambaldi, A.; Introna, M. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood, 2001, 98(12), 3383-3389.
69. Sivaraman, S.; Venugopal, P.; Ranganathan, R.; Deshpande, C. G.; Huang, X.; Jajeh, A.; Gregory, S. A.; O'Brien, T.; Preisler, H. D. Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia. Cytokines Cell Mol. Ther., 2000, 6(2), 81-87.
70. Cartron, G.; Dacheux, L.; Salles, G.; Solal-Celigny, P.; Bardos, P.; Colombat, P.; Watier, H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, 2002, 99(3), 754-758.
71. Binstadt, B. A.; Geha, R. S.; Bonilla, F. A. IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy. J. Allergy Clin. Immunol., 2003, 111(4), 697-703.
72. Treon, S. P.; Hansen, M.; Branagan, A. R.; Verselis, S.; Emmanouilides, C.; Kimby, E.; Frankel, S. R.; Touroutoglou, N.; Turnbull, B.; Anderson, K. C.; Maloney, D. G.; Fox, E. A. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J. Clin. Oncol., 2005, 23(3), 474-481.
73. O'Brien, S.; Kantarjian, H.; Keating, M. J. Purine analogs in chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia. Ann. Oncol., 1996, 7(Suppl. 6), S27-S33.
74. Leblond, V.; Choquet, S. Fludarabine in Waldenstrom's macroglobulinemia. Semin. Oncol., 2003, 30(2), 239-242.
75. Jacobs, A. Cold agglutinin hemolysis responding to fludarabine therapy. Am. J. Hematol., 1996, 53(4), 279-280.
76. Di Gaetano, N.; Xiao, Y.; Erba, E.; Bassan, R.; Rambaldi, A.; Golay, J.; Introna, M. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytoloxic activity of either drug alone. Br. J. Haematol., 2001, 114(4), 800-809.
77. Weber, D. M.; Dimopoulos, M. A.; Delasalle, K.; Rankin, K.; Gavino, M.; Alexanian, R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin. Oncol., 2003, 30(2), 243-247.
78. Swords, R.; Nolan, A.; Fay, M.; Quinn, J.; O'Donnell, R.; Murphy, P. T. Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-CD20 monoclonal antibody rituximab. Clin. Lab Haematol., 2006, 28(1), 57-59.
79. Berentsen, S.; Tjonnfjord, G. E.; Ulvestad, E. Therapy for chronic cold agglutinin disease: a prospective, non-randomized international multicentre study on the safety and efficacy of rituximab in combination with fludarabine. http://www.clinicaltrials.gov/ct/show/ NCT00373594?order=1 2006. Accessed April 2007.
80. Berentsen, S.; Tjonnfjord, G. E. Rituximab and fludarabine combination therapy for chronic cold agglutinin disease [11th congress of the European Hematology Association, Amsterdam, Abstract 0027]. Haematologica, 2006, 91 (Suppl 1), 11.
81. Kaplan, M. Eculizumab (Alexion). Curr Opin. Investig. Drugs, 2002, 3(7), 1017-1023.
82. Hillmen, P.; Young, N. S.; Schubert, J.; Brodsky, R. A.; Socie, G.; Muus, P.; Roth, A.; Szer, J.; Elebute, M. O.; Nakamura, R.; Browne, P.; Risitano, A. M.; Hill, A.; Schrezenmeier, H.; Fu, C. L.; Maciejewski, J.; Rollins, S. A.; Mojcik, C. F.; Rother, R. P.; Luzzatto, L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med., 2006, 355(12), 1233-1243.